Document is current
Any future updates will be listed below
-
Authors
Bonaventura, Jordi https://orcid.org/0000-0002-4745-0151
Lam, Sherry
Carlton, Meghan
Boehm, Matthew
Gomez, Juan L.
Solís, Oscar https://orcid.org/0000-0002-8285-5891
Sánchez-Soto, Marta https://orcid.org/0000-0003-3343-5628
Morris, Patrick J.
Fredriksson, Ida
Thomas, Craig J.
Sibley, David R. https://orcid.org/0000-0002-0624-962X
Shaham, Yavin https://orcid.org/0000-0002-8242-3319
Zarate, Carlos A. Jr.
Michaelides, Michael https://orcid.org/0000-0003-0398-4917
-
Funding
Funding for this research was provided by:
Ministry of Economy and Competitiveness | Agencia Estatal de Investigación (PID2020-117989RA-I00, RYC-2019-027371-I)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (ZIA00069)
- License Information
-
More Information
Article History
Received: 14 May 2022
Revised: 30 May 2022
Accepted: 7 June 2022
First Online: 22 June 2022
Competing interests
: CAZ is listed as a co-inventor on a patent for the use of ketamine in major depression and suicidal ideation. CAZ is listed as co-inventor on a patent for the use of (2R,6R)- hydroxynorketamine, (S)-dehydronorketamine, and other stereo- isomeric dehydro and hydroxylated metabolites of (R,S)-ketamine metabolites in the treatment of depression and neuropathic pain; and as a co-inventor on a patent application for the use of (2R,6R)-hydroxynorketamine and (2S,6S)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and posttraumatic stress disorders. He has assigned his patent rights to the US government but will share a percentage of any royalties that may be received by the government. PJM and CJT are coinventors on patents regarding the use and methods of production for (2R,6R)-hydroxynorketamine. They have assigned their patent rights to the US government but will share a percentage of any royalties that may be received by the government. MM has received research funding from AstraZeneca, Redpin Therapeutics, and Attune Neurosciences. All other authors declare no competing interests.
